公开(公告)号：EP4410976A2

公开(公告)日：2024-08-07

申请号：EP24167285.6

申请日：2014-03-14

申请人： Elixirgen Therapeutics, Inc.

发明人： KO, Minoru S.H.

IPC分类号： C12N15/09

CPC分类号： C12N2760/1884120130101 ,  A61K48/005 ,  A61K31/7088 ,  A61K38/1709 ,  C07K14/47 ,  C12N15/113 ,  C12N2310/1420130101 ,  C12N2310/53120130101 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P11/00 ,  A61P13/00 ,  A61P13/02 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P17/14 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61P21/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P25/32 ,  A61P27/02 ,  A61P27/16 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  A61P5/00 ,  A61P5/38 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P3/10

摘要： The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.

公开(公告)号：EP4335510A3

公开(公告)日：2024-06-26

申请号：EP23219258.3

申请日：2008-09-17

申请人： Amgen Inc.

发明人： PADHI, Ian Desmond ,  JANG, Graham Richard

IPC分类号： A61K39/395 ,  A61P19/08 ,  C07K16/18 ,  A61K39/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P5/00 ,  A61P7/06 ,  A61P15/00 ,  A61P19/00 ,  A61P19/02 ,  A61P19/10 ,  A61P25/00 ,  A61P25/08 ,  A61P25/32 ,  A61P29/00 ,  A61P31/08

CPC分类号： A61K2039/50520130101 ,  C07K16/18 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P15/00 ,  A61P19/00 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P25/00 ,  A61P25/08 ,  A61P25/32 ,  A61P29/00 ,  A61P3/00 ,  A61P3/04 ,  A61P31/08 ,  A61P5/00 ,  A61P7/06 ,  A61P3/10

摘要： The invention provides an anti-sclerostin antibody or sclerostin-binding fragment thereof for use in a method for treating a bone-related disorder in a human by administering the anti-sclerostin antibody or fragment thereof in an amount from 0.1 mg/kg to 20 mg/kg.

公开(公告)号：EP4335505A3

公开(公告)日：2024-06-05

申请号：EP23211768.9

申请日：2013-11-27

申请人： The Regents of the University of California

发明人： ROGAWSKI, Michael, A. ,  ZOLKOWSKA, Dorota

IPC分类号： A61K31/56 ,  A61K47/40 ,  A61P25/28 ,  A61K9/00 ,  A61K31/57 ,  A61K31/573 ,  A61K9/08

CPC分类号： A61K47/40 ,  A61K31/56 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/573 ,  A61K31/57 ,  A61P25/00 ,  A61P25/08 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/32 ,  A61P25/34

摘要： The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone.

公开(公告)号：EP3332649B1

公开(公告)日：2024-04-24

申请号：EP17201407.8

申请日：2011-03-17

IPC分类号： A23D7/01 ,  A23D9/05 ,  A23J7/00 ,  A23L33/00 ,  A23L33/115 ,  A23L33/12 ,  A61K31/201 ,  A61K31/683

CPC分类号： A23D7/011 ,  A23D9/013 ,  A23D9/05 ,  A23V2002/0020130101 ,  A61K31/201 ,  A61K31/683 ,  A23P10/35 ,  A23L33/40 ,  A23L33/115 ,  A23L33/12 ,  A61K31/202 ,  A61K31/685 ,  A61K31/575 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/32

公开(公告)号：EP3186225A1

公开(公告)日：2017-07-05

申请号：EP15836620.3

申请日：2015-08-26

申请人： The Governing Council of the University of Toronto ,  The University Court Of The University Of Aberdeen

发明人： GREIG, Iain ,  ZANDA, Matteo ,  TSENG, Chih-Chung ,  ROSS, Ruth

IPC分类号： C07D209/10 ,  A61K31/404 ,  A61P25/00 ,  A61P29/00 ,  C07D209/12 ,  C07D209/14 ,  C07D405/06 ,  C07D409/06

CPC分类号： C07D209/14 ,  A61P1/00 ,  A61P1/08 ,  A61P1/16 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P13/12 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/32 ,  A61P25/34 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D209/10 ,  C07D209/12 ,  C07D401/04 ,  C07D405/06 ,  C07D409/06

摘要： The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

摘要翻译： 本发明涉及式（I）的吲哚衍生物，其为大麻素1型受体调节剂并且可用于治疗受体调节有益的疾病; 为他们的准备过程; 包含它们的药物组合物; 以及使用它们的方法。

公开(公告)号：EP3874959B1

公开(公告)日：2024-07-10

申请号：EP21150236.4

申请日：2017-12-08

IPC分类号： A23D9/013 ,  A61K31/201 ,  A61K31/202 ,  A61K31/683 ,  A23L33/00 ,  A23L33/12 ,  A61P25/32 ,  A61P25/28 ,  A61P25/24 ,  A61P25/22 ,  A61P25/16 ,  A61P25/30 ,  A23L33/115 ,  A61K31/20

CPC分类号： A23D9/013 ,  A61K31/201 ,  A61K31/202 ,  A61K31/683 ,  A23L33/40 ,  A23L33/12 ,  A61K31/20 ,  A23L33/115 ,  A61P25/16 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/32

公开(公告)号：EP3054934B1

公开(公告)日：2024-05-22

申请号：EP14852359.0

申请日：2014-10-03

IPC分类号： A61K9/70 ,  A61K47/12 ,  A61K47/32 ,  A61K31/4174 ,  A61P25/30 ,  A61P25/36 ,  A61P25/32 ,  A61P25/34

CPC分类号： A61K47/12 ,  A61K47/32 ,  A61K31/4174 ,  A61K9/7053 ,  A61K9/7061 ,  A61P25/30 ,  A61P25/32 ,  A61P25/34 ,  A61P25/36

公开(公告)号：EP3371188A1

公开(公告)日：2018-09-12

申请号：EP16793800.0

申请日：2016-11-02

申请人： Janssen Pharmaceutica NV

发明人： BUIJNSTERS, Petrus Jacobus Johannes Antonius ,  GIJSEN, Henricus Jacobus Maria ,  DRINKENBURG, Wilhelmus, Helena Ignatius Maria ,  AHNAOU, Abdallah

IPC分类号： C07D487/04 ,  A61P25/18

CPC分类号： C07D487/04 ,  A61K45/06 ,  A61K2300/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28 ,  A61P25/32 ,  A61P25/34 ,  A61P25/36

摘要： The present invention relates to a novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivative as inhibitor of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compound, to processes for preparing such compound and compositions, and to the use of such compound and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorder.

公开(公告)号：EP3371170A1

公开(公告)日：2018-09-12

申请号：EP16791377.1

申请日：2016-11-03

申请人： F. Hoffmann-La Roche AG

发明人： GAUFRETEAU, Delphine ,  HILPERT, Hans ,  HUMM, Roland ,  KOLCZEWSKI, Sabine ,  MUSER, Thorsten ,  PLANCHER, Jean-Marc ,  STOLL, Theodor

IPC分类号： C07D401/14 ,  A61K31/404 ,  A61K31/44 ,  A61K31/506 ,  C07D403/14 ,  C07D409/14 ,  A61P25/00 ,  A61P25/18

CPC分类号： C07D409/14 ,  A61K9/0019 ,  A61K9/2018 ,  A61K9/4858 ,  A61K31/444 ,  A61K31/506 ,  A61K45/06 ,  A61K47/10 ,  A61K2300/00 ,  A61P25/08 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/32 ,  A61P25/36 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

摘要： The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.

公开(公告)号：EP3371169A1

公开(公告)日：2018-09-12

申请号：EP16790362.4

申请日：2016-11-03

申请人： F. Hoffmann-La Roche AG

发明人： GAUFRETEAU, Delphine ,  HILPERT, Hans ,  HUMM, Roland ,  KOLCZEWSKI, Sabine ,  MUSER, Thorsten ,  PLANCHER, Jean-Marc ,  STOLL, Theodor

IPC分类号： C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D498/04 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5383 ,  A61P9/00 ,  A61P25/00 ,  A61P27/00 ,  A61P31/04 ,  A61P31/12

CPC分类号： C07D403/14 ,  A61K31/506 ,  A61K45/06 ,  A61K2300/00 ,  A61P25/08 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/32 ,  A61P25/36 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/14 ,  C07D413/14 ,  C07D498/04

摘要： The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co morbid epilepsy.